Patient Counseling Section Of Labeling Should Be Limited, FDA Advises
This article was originally published in The Pink Sheet Daily
Only the most important, not necessarily the most common, side effects should be included in the section denoting what a health care provider should tell a patient, FDA’s draft guidance says; section was mandated under 2006 physician labeling rule.
You may also be interested in...
FDA's final labeling rule creates several new sections designed to facilitate physicians' drug prescribing practices
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.